Proyectos de ley › 89.ª Asamblea General
Relating to price transparency and cost-sharing for prescription drugs, and including applicability provisions
Presentado por el comité Commerce de la Cámara
Temas:Business & economyHealth care
La misma legislación: HSB 46
Dónde está ahora
- Hecho: Presentado15 de febrero de 2021
- Se detuvo: SubcomitéMurió al terminar la Asamblea General
- Sigue: Comité de la Cámara
- Sigue: Lo aprueba la Cámara
- Sigue: Comité del Senado
- Sigue: Lo aprueba el Senado
- Sigue: A gobernador(a)
- Sigue: Firmado como ley
Murió al terminar la sesión La sesión de 2022 terminó el 24 de mayo de 2022, la última sesión ordinaria de la Asamblea General. Los proyectos que no pasaron por ambas cámaras murieron. ¿Qué es el embudo (funnel)?
Qué contiene
La explicación oficial está en inglés; todavía no hay resumen en palabras sencillas.
This bill relates to price transparency and cost-sharing for prescription drugs. The bill requires a manufacturer to file an annual report with the commissioner of insurance (commissioner) that discloses the wholesale acquisition cost for all prescription drugs manufactured by the manufacturer that were sold to a person in this state in the immediately preceding calendar year. “Wholesale acquisition cost” or “cost” is defined in the bill as the manufacturer’s list price for a prescription drug for wholesalers or direct purchasers in the United States, not including prompt pay or other discounts, rebates, or reductions in price, for the most recent month for which the information is available, as reported in wholesale price guides or other publications of drug or biological pricing data.
Lea la explicación completa
Within calendar days of receipt, the commissioner is required to publish the information from the annual reports on a publicly accessible internet site. If a prescription drug sold to a person in this state has a cost of $100 or more for a 30-day supply and the cost increases percent or more over the three preceding calendar years, or increases percent or more in the preceding calendar year, the manufacturer of the prescription drug must file a report with the commissioner within calendar days of the date on which the or percent increase in cost occurs. This requirement is applicable to all manufacturers that manufactured prescription drugs that are sold to a person in this state on or after January 1, 2021. The report must include the information detailed in the bill. Certain information provided by a manufacturer, as detailed in the bill, is considered a confidential record and is required to be protected as a trade secret. Within calendar days of receipt, the commissioner is required to publish the nonconfidential information on the same publicly accessible internet site on which the manufacturer’s annual report information is published. The bill requires each health carrier to submit an annual report by February to the commissioner that contains information as detailed in the bill across all of the health carrier’s health benefit plans. An authorized insurer or an authorized third-party administrator that administers a multiple employer welfare arrangement must submit the required report on behalf of the multiple employer welfare arrangement that the insurer or the third-party administrator administers. This requirement is applicable to all health benefit plans providing for third-party payment or prepayment of health or medical expenses that provide a prescription drug benefit that have been delivered, issued for delivery, continued, or renewed in this state on or after January 1, 2021. “Health carrier” is defined in the bill as an entity subject to the insurance laws and regulations of this state, or subject to the jurisdiction of the commissioner, including an insurance company offering sickness and accident plans, a health maintenance organization, a nonprofit health service corporation, a plan established pursuant to Code chapter 509A for public employees, or any other entity providing a plan of health insurance, health care benefits, or health care services. As detailed in the bill, certain information provided by a health carrier, or an authorized insurer or an authorized third-party administrator on behalf of a multiple employer welfare arrangement, is considered a confidential record and must be protected as a trade secret. Prior to May of each year, the commissioner must publish the nonconfidential data received by the commissioner on the same publicly accessible internet site on which the manufacturers’ information is published. The data must be aggregated from the annual reports submitted by all health carriers. The bill directs the commissioner to adopt rules as necessary to administer the requirements outlined in the bill. The bill details the commissioner’s authority, and the process to enforce that authority, for manufacturers’, manufacturers’ agents’, health carriers’ or health carriers’ agents’ violations of a provision of the bill, a rule adopted by the commissioner, or of an order issued by the commissioner. The bill also allows the commissioner, or the court, to order payment of penalties for certain violations as outlined in the bill. Manufacturers, manufacturer’s agents, health carriers, and health carrier’s agents may request a contested case proceeding, or seek judicial review of an action of the commissioner, in certain circumstances as detailed in the bill. The bill also requires a carrier to include all cost-sharing amounts paid by an enrollee of a health plan, or by another person on behalf of an enrollee, as part of the carrier’s calculation of an enrollee’s contribution to the enrollee’s applicable cost-sharing requirement. This does not apply to cost-sharing incurred for a specialty drug or a prescription drug for which an A-rated generic equivalent or an interchangeable biological product is available. “Cost-sharing requirement” is defined in the bill as any copayment, coinsurance, deductible, or other out-of-pocket expense obligation required of or on behalf of an enrollee in order for the enrollee to receive a specific health care service, including a prescription drug, covered by the enrollee’s health plan. This requirement applies to all health plans delivered, issued for delivery, continued, or renewed in this state on or after January 1, 2022. The bill excludes state-regulated high-deductible health plans (HDHP) from the requirement if it will result in the plan not qualifying as an HDHP under section 223 of the Internal Revenue Code. The bill also prohibits application of the requirement to a carrier or to a circumstance in a manner that will conflict with a federal law or a federal regulation.
Lo que cambia del Código de Iowa (Iowa Code)
Crea§510D.1§510D.2§510D.3§510D.4§510D.5§510D.6§510E.1§510E.2§510E.3§510E.4§510E.5§514M.1§514M.2§514M.3
Cabildeo
2 a favor · 0 en contra · 31 indecisos · Quiénes →
Family tree
Tried before
Study bill
89th General Assembly
Earlier and later bills are matched by wording or an identical title.
Tried before
This idea has been filed in an earlier General Assembly. None got through a chamber.
- HF 2551 Relating to price transparency for prescription drugs and cost-sharing calculations by car…88th General Assembly · Approved by committee · very similarCleared committee
Similar bills this General Assembly
- HF 464 Relating to price transparency and cost-sharing for prescription drugs, and including appl…89th General Assembly · In committeeVery similar
Matched by wording or an identical title.